PMID- 36660627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 24
DP  - 2022 Dec
TI  - Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the 
      treatment of locally advanced cervical cancer.
PG  - 1322
LID - 10.21037/atm-22-5739 [doi]
LID - 1322
AB  - BACKGROUND: Platinum-based concurrent chemoradiotherapy (CCRT) is the primary 
      treatment for locally advanced cervical cancer (LACC). Improving the efficacy of 
      LACC treatment is the focus of clinical research, and nimotuzumab combined with 
      CCRT is a new research direction. This retrospective study aimed to investigate 
      the efficacy and safety of nimotuzumab combined with CCRT compared with CCRT 
      alone for treating LACC. METHODS: Data from LACC patients treated at The 
      Affiliated Hospital of Qingdao University from March 2017 to December 2019 were 
      collected, and patients were assigned to either a nimotuzumab plus 
      chemoradiotherapy (N + CCRT) group or a CCRT group. Baseline data were also 
      collected. Patients were followed up every 3 to 6 months by imaging examination 
      or telephone. The primary endpoints were overall survival (OS) and 
      progression-free survival (PFS), and the secondary endpoints were complete 
      response rate (CRR), objective response rate (ORR), and incidence of adverse 
      events (AEs). RESULTS: A total of 120 patients (65 in the N + CCRT group and 55 
      in the CCRT group) were enrolled, which baseline data were no statistical 
      difference between the two groups (P>0.05). In the N + CCRT group, the 1-, 2-, 
      and 3-year cumulative survival rates were 98.46%, 95.38%, and 90.50%, 
      respectively, and the 1-, 2-, and 3-year cumulative PFS rates were 89.23%, 
      83.08%, and 79.73%, respectively. The CRR was 86.15% (56/65), and the ORR was 
      92.31% (60/65). In the CCRT group, the 1-, 2-, and 3-year cumulative survival 
      rates were 94.55%, 87.27%, and 78.18%, respectively, and the 1-, 2-, and 3-year 
      cumulative PFS rates were 81.82%, 69.09%, and 59.69%, respectively. The CRR was 
      70.91% (39/55), and the ORR was 87.27% (48/55). The CRR (86.15% vs. 70.91%, 
      P=0.040) and 3-year cumulative PFS rates (79.73% vs. 59.69%, P=0.039) were 
      significantly higher in the N + CCRT group than in the CCRT group. The incidences 
      of various AEs were from 5.45% to 95.38%, without significant difference in AEs 
      between the two groups (P>0.05). CONCLUSIONS: Nimotuzumab combined with CCRT 
      enhanced the PFS and CRR of LACC patients and was well tolerated. The results can 
      provide reference for clinical treatment of LACC.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Jiang, Yuqi
AU  - Jiang Y
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Jiang, Peng
AU  - Jiang P
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Chen, Zhiying
AU  - Chen Z
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Cui, Huanliang
AU  - Cui H
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
FAU - Zhang, Yongchun
AU  - Zhang Y
AD  - Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, 
      Qingdao, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9843379
OTO - NOTNLM
OT  - Nimotuzumab
OT  - adverse events (AEs)
OT  - concurrent chemoradiotherapy (CCRT)
OT  - locally advanced cervical cancer (LACC)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-5739/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/01/21 06:00
MHDA- 2023/01/21 06:01
PMCR- 2022/12/01
CRDT- 2023/01/20 02:16
PHST- 2022/10/31 00:00 [received]
PHST- 2022/12/07 00:00 [accepted]
PHST- 2023/01/20 02:16 [entrez]
PHST- 2023/01/21 06:00 [pubmed]
PHST- 2023/01/21 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - atm-10-24-1322 [pii]
AID - 10.21037/atm-22-5739 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Dec;10(24):1322. doi: 10.21037/atm-22-5739.